Can vitamin e tame COVID-19 inflammation? early trial hints yes
NCT ID NCT07412574
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tested whether high doses of vitamin E (alpha-tocopherol) could reduce C-reactive protein (CRP), a marker of inflammation, in 56 adults with COVID-19. Participants were randomly assigned to receive vitamin E or a placebo. The results suggest that vitamin E may help lower CRP levels, but because the trial was small and preliminary, more research is needed to confirm these findings.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- high-dose vitamin E (alpha-tocopherol)
- What this could lead to
- If confirmed, this could point toward a simple, low-cost way to reduce inflammation in COVID-19 patients.
- What could go wrong
- This is a very early, small trial (56 people) with no long-term follow-up. The results are preliminary and may not hold up in larger studies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Faculty of Medicine
Xalapa, Veracruz, 91120, Mexico
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Five years on: how does long COVID evolve?
- Can a targeted pill tame severe COVID-19?
- Can an organic compound tame COVID-19 in High-Risk patients?
- Could exercise retrain the heart in long COVID?
- Can a new drug shield lungs from COVID-19's worst damage?
- Can paxlovid hold the line against severe COVID-19 outside the lab?